Cook Brian, Riggs Melanie, Holley K C, Knaggs Helen, Diwakar Ganesh, Lephart Edwin D
Nu Skin Global Research and Innovation, Nu Skin Enterprises, Provo, UT, USA.
Department of Cell Biology and Physiology, The Neuroscience Center, College of Life Sciences, Brigham Young University, Provo, UT, 84602, USA.
Dermatol Ther (Heidelb). 2025 Jan;15(1):189-200. doi: 10.1007/s13555-024-01332-8. Epub 2024 Dec 25.
Retinol has a long history of treating skin conditions, including photoaging. However, skin irritation with repeated use of retinol is well documented. The present study assessed the effectiveness of a novel topical formulation, referred to as retinol topical formulation (RTF), to improve the quality of skin health. The RTF was composed of a low dose retinol, a synthetic retinoid ester, a pea peptide, and an antioxidant blend.
In vitro assessment of RTF on human skin co-cultures (human keratinocytes, melanocytes, and dermal fibroblasts) identified gene expression levels and skin biomarkers after 24 h exposure. An 8-week clinical study was conducted to evaluate once-nightly application of the RTF for short-term and long-term benefits in 30 adult subjects between 35 and 70 years of age (21 female, 9 male). Skin evaluations were conducted via bioinstrumentation (for hydration, transepidermal water loss and elasticity) and at 0, 1-, 2-, 4-, and 8-week self-assessment questionnaires and photo-imaging analysis were performed.
RTF treatment of skin in vitro co-cultures upregulated aquaporin-3, PER1, collagen, and elastin, and downregulated expression of MMP1 and the pigmentation genes TYRP1 and MITF. The clinical assessment significantly improved hydration, transepidermal water loss, and elasticity along with incremental but significant increases in nine skin parameters (hydration, clarity, radiance/glow, smoothness, brightness, texture, appearance of pores, dark spots/hyperpigmentation, and skin tone evenness from baseline) with continuous use over 8 weeks compared to baseline values.
The RTF in vitro analysis showed significant positive changes for several skin biomarkers, and the clinical assessment showed RTF significantly improved the visible signs of dermal aging, without irritation.
视黄醇用于治疗包括光老化在内的皮肤疾病已有很长历史。然而,反复使用视黄醇会引起皮肤刺激,这一点已有充分记录。本研究评估了一种新型外用制剂(称为视黄醇外用制剂,RTF)改善皮肤健康质量的有效性。RTF由低剂量视黄醇、一种合成类视黄醇酯、一种豌豆肽和一种抗氧化剂混合物组成。
对人皮肤共培养物(人角质形成细胞、黑素细胞和真皮成纤维细胞)进行RTF的体外评估,确定暴露24小时后的基因表达水平和皮肤生物标志物。进行了一项为期8周的临床研究,以评估30名年龄在35至70岁之间的成年受试者(21名女性,9名男性)每晚一次使用RTF的短期和长期益处。通过生物仪器(用于测量皮肤水合作用、经表皮水分流失和弹性)进行皮肤评估,并在第0、1、2、4和8周进行自我评估问卷调查以及照片成像分析。
RTF处理体外共培养的皮肤上调了水通道蛋白3、PER1、胶原蛋白和弹性蛋白,并下调了MMP1以及色素沉着相关基因TYRP1和MITF的表达。临床评估显示,与基线值相比,连续使用8周后,皮肤水合作用、经表皮水分流失和弹性显著改善,九个皮肤参数(水合作用、透明度、光泽度、光滑度、亮度、质地、毛孔外观、黑斑/色素沉着和肤色均匀度)也有逐渐但显著的增加。
RTF的体外分析显示,几种皮肤生物标志物有显著的积极变化,临床评估表明RTF显著改善了皮肤老化的可见迹象,且无刺激作用。